PP
XLRN

Paloma Partners’s Acceleron Pharma XLRN Stock Holding History

Paloma Partners’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,995
Closed -$450K – 2427
2020
Q3 		$450K Sell
3,995
-100,973
-96% -$10.1M 0.01% 1239
2020
Q2 		$10M Buy
+104,968
New +$10.1M 0.17% 108
2020
Q1 		– Sell
-4,486
Closed -$238K – 2316
2019
Q4 		$238K Buy
+4,486
New +$205K ﹤0.01% 1891

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Paloma Partners's XLRN Position: Q4 2020 in Review

Paloma Partners sold out of Acceleron Pharma (XLRN) in Q4 2020, closing a stake of 3,995 shares — an estimated $450K sold.

Paloma Partners first reported a position in XLRN in Q4 2019 and held it in 3 quarters. The position peaked at $10M in Q2 2020. 253 funds tracked by Wall St. Rank hold XLRN as of Q4 2020.

  • Paloma Partners reported no remaining Acceleron Pharma position as of Q4 2020 after selling out during the quarter.
  • Paloma Partners sold 3,995 Acceleron Pharma shares in Q4 2020, an estimated $450K.
  • Paloma Partners first reported a position in Acceleron Pharma in Q4 2019 and held it in 3 quarters.
  • Paloma Partners's Acceleron Pharma position peaked at $10M in Q2 2020.
  • 253 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2020.

Based on Paloma Partners's 13F filing for Q4 2020, filed 16 Feb 2021.